A cross-sectional and longitudinal study between association of n-3 polyunsaturated fatty acids derived from fish consumption and high-density lipoprotein heterogeneity

Shigemasa Tani1,2,3 · Rei Matsuo2,3 · Kenji Kawauchi2,3 · Tsukasa Yagi2,3 · Wataru Atsumi2,3 · Atsushi Hirayama3

Received: 24 July 2017 / Accepted: 10 November 2017 / Published online: 20 November 2017 © The Author(s) 2017. This article is an open access publication

Abstract
Decreased high-density lipoprotein (HDL) particle size, cholesterol poor, apolipoprotein A-I-rich HDL particles leading to smaller HDL particle size, may be associated with an anti-atherosclerotic effect. The data are sparse regarding the relationship between n-3 polyunsaturated fatty acids [n-3 PUFAs: eicosapentaenoic acid (EPA), docosahexaenoic acid (DHA)] and HDL particle size. This study was designed as a hospital-based cross-sectional study to investigate the relationship between the serum levels of n-3 PUFAs and the HDL-cholesterol/apolipoprotein A-1 ratio, as estimated by the HDL particle size, in patients with the presence of one or more risk factors for atherosclerotic cardiovascular disease (ASCVD). Six hundred and forty sequential patients were enrolled in this study. The serum levels of EPA and DHA showed a strong correlation \((r = 0.736, p < 0.0001)\). However, in a multivariate regression analysis after adjustment for ASCVD risk factors, increased serum DHA \((\beta = -0.745, p = 0.021)\), but not serum EPA \((\beta = -0.414, p = 0.139)\) or EPA + DHA \((\beta = 0.330, p = 0.557)\) level, was identified as an independent indicator of decreased HDL particle size. In 476 patients followed up for at least 6 months, the absolute change (\(\Delta\)) in the HDL-cholesterol/apolipoprotein A-1 ratio decreased significantly as the quartile of the \(\Delta\) DHA level increased \((p = 0.014)\), whereas no significant difference in the \(\Delta\) HDL-cholesterol/apolipoprotein A-1 ratio was noted with the increase in the quartile of the \(\Delta\) EPA level. Moreover, a multivariate regression analysis identified increased DHA level and decreased estimated low-density lipoprotein (LDL) particle size measured relative to the mobility value of LDL with polyacrylamide gel electrophoresis (i.e., relative LDL migration: LDL-Rm value), as independent predictors of decreased HDL-cholesterol/apolipoprotein A-1 ratio \((\beta = -0.171, p = 0.0003\) and \(\beta = -0.142, p = 0.002\)). The results suggest that increased serum DHA level, but not EPA level, might be associated with decreased HDL-cholesterol/apolipoprotein A-1 ratio, an indicator of estimated HDL particle size. Further studies are needed to investigate the useful clinical indices and outcomes of these patients.

Clinical Trial Registration Information UMIN (http://www.umin.ac.jp/), Study ID: UMIN000010603.

Keywords
Apolipoprotein A-1 · Docosahexaenoic acid · Eicosapentaenoic acid · High-density lipoprotein · n-3 Polyunsaturated fatty acid

Introduction

The Japanese people are one of the leading nations with high levels of fish consumption in the world [1], and it has been suggested that the cardiovascular protective effects of n-3 polyunsaturated fatty acids (n-3 PUFAs) such as eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) derived from fish intake have bearing on the suppression of coronary artery disease (CAD) morbidity [2, 3].

Not only low-density lipoprotein (LDL) metabolism but high-density lipoprotein (HDL) metabolism as well is closely involved in the progress and suppression of
arteriosclerosis [4]. We previously reported better responses of Japanese subjects to lipid lowering treatment in suppressing progress of coronary arteriosclerosis, compared with Europeans and Americans, and also described the significant involvement of improved HDL metabolism in those therapeutic responses [5]. Our recent study reports that a group of subjects showing high serum levels of EPA and DHA had low morbidity of CAD and high serum levels of apolipoprotein A-1 (apoA-1), a major functional carrier protein component of HDL particles [6]. However, there have been no studies to examine changes in HDL particle size that has a great bearing upon the cholesterol efflux capacity in the reverse cholesterol transport (RCT) system with a major functional role for the antiatherosclerotic effect of HDL [7, 8]. Reports dealing with the relationship of n-3 PUFAs with HDL particle size are few as yet, and there is no unanimity of view in this regard [9–12].

In view of the inverse correlation between serum HDL-C level and CAD morbidity based on a number of epidemiological studies [13], the “HDL-C hypothesis” that an increase in serum HDL-C level results in attenuation of the risk of CAD has long been supported [14]. Nevertheless, large-scale clinical studies to examine the relation of serum HDL-C level to suppression of occurrence of CAD with the results disproving the hypothesis have followed one another [15–17]. It has been shown in recent years that the more pronounced is the HDL-cholesterol efflux capacity, the less conspicuous is the carotid intima-media thickness [18] and the less frequent are CAD events [19]. It is now recognized that, for prevention of atherosclerotic cardiovascular disease (ASCVD), it is important not so much to increase the serum HDL-C level as to improve the function of HDL [14].

It has been reported in recent years that small HDL particles with scanty lipid components and high protein contents (low HDL-C/apoA-1 ratio) are involved in the prevention of ASCVD [20–22] than large HDL particles.

We thus set up a hypothesis that the ASCVD-suppressive effect of n-3 PUFAs acquired through fish intake may have an association with the HDL particle size as an indicator of HDL function, or the low HDL-C/apoA-1 ratio. The aim of the present study was to examine the relationship of the HDL-C/apoA-1 ratio as a marker of HDL particle estimation and n-3 PUFAs (EPA, DHA) using cross-sectional and longitudinal study procedures.

Method

Study design and populations

This study was designed as a hospital-based cross-sectional and longitudinal studies to investigate the relationships between the serum HDL-C/apoA1 ratio as estimated the HDL particle size and serum n-3 PUFAs (EPA and DHA) levels in patients with one or more risk factors for ASCVD. Furthermore, we examined the relationship between the changes in the serum n-3 PUFAs level and the change in the serum HDL-C/apoA1 ratio in the cases that were available for additional measurements 6 months later. This study is a subanalysis of our previous study [6]. The study was conducted using a sample of 700 consecutive outpatients who had undergone regular examinations and blood examinations at the Cardiovascular Center of Nihon University Surugadai Hospital between June and October 2009.

The criterion for patient registration in the cross-sectional study was the presence of one or more risk factors for atherosclerosis. The diagnostic criteria for coronary risk factors were as follows: a diagnosis of hypertension was made when the systolic pressure was ≥ 140 mmHg, the diastolic pressure was ≥ 90 mmHg, or the patient was taking antihypertensive medication. Diabetes mellitus (DM) was defined as a fasting plasma glucose concentration ≥ 126 mg/dL and an HbA1c ≥ 6.5% or current treatment with anti-diabetic agents. A diagnosis of dyslipidemia was made when the LDL cholesterol (LDL-C) level was ≥ 140 mg/dL, triglyceride (TG) level was ≥ 150 mg/dL, the HDL-C level was ≤ 40 mg/dL, or if the patient was already taking lipid-lowering medication. A diagnosis of hyperuricemia was made when the serum uric acid level was ≥ 7.0 mg/dL or the patient was taking medications. The severity of chronic kidney disease (CKD) was determined based on the estimated glomerular filtration rate (eGFR) using the abbreviated Modification of Diet in Renal Disease (MDRD) Study equation, modified by a Japanese coefficient [23]; CKD was defined as eGFR < 60 mL/min/1.73 m². Obesity was defined as a body mass index (BMI) ≥ 25 kg/m².

Patients were not enrolled if they met any of the following exclusion criteria: hepatic dysfunction (alanine aminotransferase and aspartate aminotransferase ≥ 2 times the upper limit of the normal values), known malignant disease, refusal to provide consent for participation in the study, current treatment with n-3 PUFAs, or the diagnosis of acute coronary syndrome within 3 months prior to the study. The Nihon University Surugadai Hospital Ethics Committee approved the design and purpose of the study.

Measurement of laboratory parameters

Fasting blood samples were collected early in the morning after a 12-h fast. The serum fatty acid levels were measured using capillary gas chromatography (SRL Co., Ltd., Tokyo, Japan). The serum total cholesterol (TC), HDL-C, and TG levels were measured using standard methods. LDL-C levels were estimated using the Friedewald formula [24]. The RLP-C level was measured using an immunoadsorption assay (SRL). The serum apo and Lp (a) levels were
determined using turbidimetric latex agglutination assays (Daiichi Pure Chemicals Co., Ltd., Tokyo, Japan). The malondialdehyde-modified LDL (MDA-LDL) level was measured using an enzyme-linked immunosorbent assay (SRL). The high-sensitivity C-reactive protein (hs-CRP) level was measured using a nephelometric assay (Behring Diagnostic Marburg, Germany). The relative LDL migration (LDL-Rm value), an indicator of LDL particle size, was measured relative to the mobility value of LDL by performing polyacrylamide gel electrophoresis with the LipoPhor system (JOKO, Tokyo, Japan). The LDL-Rm value was calculated as the distance between the VLDL peak and the LDL peak divided by the distance between the VLDL peak and the HDL peak. A decrease in the LDL-Rm value indicates an increase in the LDL particle size [25, 26].

Statistical analysis

Data were expressed as the mean ± standard deviation for continuous variables and as percentages for discrete variables. For variables with a significantly skewed distribution, the data were expressed as the interquartile range. In a subset analysis performed according to quartiles of the serum markers, we used an analysis of variance (ANOVA) followed by Bonferroni’s adjustment for covariates if differences had been detected in the serum markers. A multivariate regression analysis was used to assess determinants of the independent variables of the HDL-C/apoA-1 ratio, as the estimated HDL particle size. The HDL-C/apoA-1 ratio was considered as the dependent variable, and the independent variables included age, gender, ASCVD risk factors, and the serum EPA, DHA, and EPA + DHA levels. In 476 patients followed up for at least 6 months, univariate and multivariate regression analyses were also performed to identify independent variables associated with the absolute change (Δ) in HDL/apoA-1 level. A p value less than 0.05 was considered to indicate statistical significance. All the statistical analyses were performed using the SPSS software program (SPSS Inc., Chicago, IL, USA) for Windows (version 12.0.1).

Results

Patients

We excluded 60 subjects from the analysis because of missing laboratory data. Therefore, finally, 640 subjects were included in the analysis. The patient characteristics and laboratory profile are shown in Tables 1 and 2. The EPA level ranged from 6.2 to 373.5 μg/mL [median, interquartile range; 63.0 μg/mL (40.1/92.6)], and the DHA level ranged from 35.7 to 451.8 μg/mL [128.9 μg/mL (100.8/60.8)]. In addition, there were no cardiovascular

Table 1 Patient characteristics \((N = 640)\)

| Male/female, \(n\) (%) | 448 (68)/212 (32) |
|------------------------|--------------------|
| Age (years)            | 62.4 ± 14.2        |
| BMI (kg/m²)            | 24.0 ± 3.9         |
| Hypertension, \(n\) (%)| 462 (70)           |
| Diabetes mellitus, \(n\) (%)| 179 (27)     |
| HbA1c (%)              | 5.97 ± 0.76        |
| Current smoking, \(n\) (%)| 94 (14)        |
| Dyslipidemia, \(n\) (%)| 408 (62)           |
| eGFR (ml/min/1.73 m²)  | 70.7 ± 18.4        |
| CKD ≥ stage 3, \(n\) (%)| 173 (27)        |
| Number of risk factors | 2.5 ± 1.4          |
| Coronary artery disease, \(n\) (%)| 145 (22)       |
| Concomitant drug, \(n\) (%)| 186 (28)       |
| Anti-platelets          | 309 (47)           |
| ACEs/ARBs               | 140 (21)           |
| β blockers              | 333 (50)           |
| Calcium channel blockers| 324 (49)           |

BMI body mass index, Hb hemoglobin, eGFR estimated glomerular flow rate, CKD chronic kidney disease, ACE-I angiotensin converting enzyme inhibitor, ARB angiotensin receptor blocker

Table 2 Laboratory profile

| Lipids                  |                 |
|-------------------------|-----------------|
| TC (mg/dL)              | 195 ± 37        |
| LDL-C (mg/dL)           | 110 ± 30        |
| HDL-C (mg/dL)           | 58 ± 17         |
| TG (mg/dL)*             | 115 (86/150)    |
| Non-HDL-C (mg/dL)       | 137 ± 34        |
| MDA-LDL (U/L)           | 109 ± 44        |
| Lp (a) (mg/dL)*         | 11 (5/25)       |
| RLP-C (mg/dL)*          | 5.3 (4.0/7.7)   |

| Apolipoproteins (mg/dL) |                 |
|-------------------------|-----------------|
| apoA-1                  | 147 ± 30        |
| apo B                   | 90 ± 21         |
| apo C-II                | 4.5 ± 1.9       |
| apo C-III               | 10.0 ± 3.3      |

| Inflammatory markers    |                 |
|-------------------------|-----------------|
| hs-CRP (mg/L)*          | 0.5 (0.3/1.2)   |

| PUFAs (μg/mL)           |                 |
|-------------------------|-----------------|
| EPA*                    | 63 (40/93)      |
| DHA*                    | 129 (101/161)   |
| AA                      | 163 ± 44        |

| EPA/AA*                 | 0.397 (0.246/0.608) |

TC total cholesterol, LDL low-density lipoprotein, HDL high-density lipoprotein, MDA malondialdehyde-modified, Lp lipoprotein, RLP remnant-like particle, apo apolipoprotein, hs-CRP hypersensitive C-reactive protein, PUFA polyunsaturated fatty acids, EPA eicosapentaenoic acid, DHA docosahexaenoic acid, AA arachidonic acid

*Median; interquartile range in parentheses
events during the 6-month follow-up period in the 476 patients followed up for at least 6 months.

Multivariate regression analysis of the relationship between HDL heterogeneity and serum n-3 PUFA levels

The serum levels of EPA and DHA showed a strong correlation ($r = 0.736, p < 0.0001$). However, in the multivariate analysis after adjustment for ASCVD risk factors, serum DHA, but not serum EPA or EPA + DHA, was identified as an independent indicator of HDL particle size (Table 3). Associations between HDL particle size and serum n-3 PUFAs levels are shown in Figs. 1 and 2.

Comparison of the absolute changes of the serum HDL-C/apoA-1 ratio according to the quartiles with the absolute change ($\Delta$) in serum DHA and EPA levels

Among the subjects of this cross-sectional study, we investigated the association between the absolute change ($\Delta$) in DHA quartile and the $\Delta$ serum HDL-C/apoA-1 ratio in 476 patients who could be followed up for at least 6 months. The $\Delta$ serum DHA level ranged from −163.5 to 151.0 ng/dL (mean ± SD 2.6 ± 37.7 ng/dL). The patients were divided into quartiles according to the $\Delta$ serum DHA level, as follows: quartile 1, −163.5 to −17.5 ng/dL ($n = 115$), quartile 2, −17.4 to 2.8 ng/dL ($n = 117$), quartile 3, 2.9 to 20.9 ng/dL ($n = 160$), and quartile 4, 21.0 to 451.8 ng/dL ($n = 160$). The serum HDL-C level tended to increase as the serum DHA quartile increased, but it did not reach statistical significance. While the serum apoA-1 level increased significantly as the serum DHA quartile increased. The serum HDL-C/apoA-1 ratio accordingly decreased significantly as the serum DHA quartile increased. *HDL-C high-density lipoprotein cholesterol, apoA-1 apolipoprotein A-1, DHA docosahexaenoic acid

### Table 3 Multivariate regression analysis of the relationship between HDL-heterogeneity and the serum n-3 PUFA levels ($N = 640$)

| Independent variable | $\beta$ | $p$ value |
|----------------------|--------|-----------|
| Male gender          | −0.262 | <0.001    |
| Age                  | −0.117 | 0.003     |
| BMI                  | −0.248 | <0.001    |
| Hypertension         | −0.082 | 0.026     |
| Diabetes mellitus    | −0.037 | 0.297     |
| Dyslipidemia         | −0.162 | 0.0005    |
| Current smoking      | −0.072 | 0.039     |
| Lipid-modifying drugs| −0.002 | 0.961     |
| EPA*                 | 0.414  | 0.139     |
| DHA*                 | −0.745 | 0.021     |
| EPA + DHA*           | 0.330  | 0.557     |

The abbreviations are the same as in Tables 1 and 2, $\beta =$ standard partial regression coefficient, multiple $R = 0.566$; $F = 25.744$; $p < 0.0001$

* Log-transformed value was used

### Fig. 1 Association of the HDL-C/apoA-1 ratio with the serum DHA level.

The patients were divided into quartiles of the DHA concentration. The DHA according to quartile was as follows: 35.7–100.7 μg/mL (quartile 1: $n = 160$), 100.8–128.7 μg/mL (quartile 2: $n = 160$), 128.9–160.5 μg/mL (quartile 3: $n = 160$), and 160.7–451.8 μg/mL (quartile 4: $n = 160$). The serum HDL-C level tended to increase as the serum DHA quartile increased, but it did not reach statistical significance. While the serum apoA-1 level increased significantly as the serum DHA quartile increased. The serum HDL-C/apoA-1 ratio accordingly decreased significantly as the serum DHA quartile increased. *HDL-C high-density lipoprotein cholesterol, apoA-1 apolipoprotein A-1, DHA docosahexaenoic acid

### Fig. 2 Comparison of the absolute changes of the serum HDL-C/apoA-1 ratio according to the quartiles with the absolute change ($\Delta$) in serum DHA and EPA levels.

Among the subjects of this cross-sectional study, we investigated the association between the absolute change ($\Delta$) in DHA quartile and the $\Delta$ serum HDL-C/apoA-1 ratio in 476 patients who could be followed up for at least 6 months. The $\Delta$ serum DHA level ranged from −163.5 to 151.0 ng/dL (mean ± SD 2.6 ± 37.7 ng/dL). The patients were divided into quartiles according to the $\Delta$ serum DHA level, as follows: quartile 1, −163.5 to −17.5 ng/dL ($n = 115$), quartile 2, −17.4 to 2.8 ng/dL ($n = 117$), quartile 3, 2.9 to 20.9 ng/dL ($n = 160$), and quartile 4, 21.0 to 451.8 ng/dL ($n = 160$). The serum HDL-C level tended to increase as the serum DHA quartile increased, but it did not reach statistical significance. While the serum apoA-1 level increased significantly as the serum DHA quartile increased. The serum HDL-C/apoA-1 ratio accordingly decreased significantly as the serum DHA quartile increased. *HDL-C high-density lipoprotein cholesterol, apoA-1 apolipoprotein A-1, DHA docosahexaenoic acid

### Table 3 Multivariate regression analysis of the relationship between HDL-heterogeneity and the serum n-3 PUFA levels ($N = 640$)

| Independent variable | $\beta$ | $p$ value |
|----------------------|--------|-----------|
| Male gender          | −0.262 | <0.001    |
| Age                  | −0.117 | 0.003     |
| BMI                  | −0.248 | <0.001    |
| Hypertension         | −0.082 | 0.026     |
| Diabetes mellitus    | −0.037 | 0.297     |
| Dyslipidemia         | −0.162 | 0.0005    |
| Current smoking      | −0.072 | 0.039     |
| Lipid-modifying drugs| −0.002 | 0.961     |
| EPA*                 | 0.414  | 0.139     |
| DHA*                 | −0.745 | 0.021     |
| EPA + DHA*           | 0.330  | 0.557     |

The abbreviations are the same as in Tables 1 and 2, $\beta =$ standard partial regression coefficient, multiple $R = 0.566$; $F = 25.744$; $p < 0.0001$

* Log-transformed value was used
Univariate and multivariate regression analyses to identify factors correlated with the absolute change in the serum HDL-C/apoA-1 ratio

In this cross-sectional study, we confirmed that increased serum DHA level was an important factor which causes a decrease in HDL particle size. Therefore, we investigated the relationship between the absolute changes (Δ) in the serum HDL level and the Δ serum HDL-C/apoA-1 ratio in order to examine their causal relationships, using a longitudinal method. To investigate the effects of the increase and decrease of the serum DHA level on the Δ serum HDL-C/apoA-1 ratio, we carried out univariate and multivariate regression analyses using the Δ serum HDL-C/apoA-1 ratio as a dependent variable and the Δ serum DHA level as an independent variable, with adjustments for gender, age, ASCVD risk factors, and the Δ LDL-migration index (LDL-Rm value), as indicators of LDL-particle size.

In 476 patients who could be followed up at least 6 months after this cross-sectional study. These analyses revealed that an increased serum DHA level and LDL-Rm value are independent predictors of a decrease in the serum HDL-C/apoA-1 ratio (Table 4).

Association of the HDL-C/apoA-1 ratio and LDL-Rm value with the serum TG level

Next, we investigated the relationship between HDL, LDL particle size, and the serum TG level which greatly affects the HDL- and LDL metabolism. The serum TG level was negatively correlated with the HDL-C/apoA-1 ratio and positively correlated with the LDL-Rm value (Fig. 4a, c). Furthermore, in the 476 patients followed up for at least 6 months, the Δ TG level showed a similar negative correlation with the Δ HDL-C/apoA-1 ratio and a similar positive correlation with the Δ LDL-Rm value (Fig. 4b, d).

Discussion

In this study, we have shown the following points. An elevated serum DHA concentration was found to be an independent prognostic factor for decrease in the HDL-C/
apoA-1 ratio as an estimate of the HDL particle size whereas an increase in the serum EPA concentration did not prove to be a prognostic factor. These findings suggest that HDL in a group of subjects showing high serum DHA levels represents smaller particles.

Furthermore, an additional study with a longitudinal method revealed that elevated DHA levels were an independent predictor of decreased HDL particle size. Due to its observational design, this study was unable to establish a causal relationship between the results, but the combination of the results of the 2 studies with different (cross-sectional and longitudinal) designs strongly suggests that an increase in the serum DHA level was associated with a decrease of the HDL particle size in patients with one or more risk factors for ASCVD.

No unanimity of opinion has been achieved in reports dealing with the relationship between n-3 PUFAs and HDL particle size (intervention studies with administration of n-3 PUFAs, or association with serum n-3 PUFAs concentration) [9–12], or association between HDL particle size and development of CAD [27–30]. This may be attributed to disparities in the characteristics of study subjects (e.g., healthy subjects, a history of CAD) or use of different assay methods for evaluating HDL particle size. Superko et al. reported in their review article that the lack of unanimity of views on the results of clinical studies examining n-3 PUFAs and their ASCVD-suppressing effects came from differences in baseline serum n-3 PUFAs levels and dose of n-3 PUFAs in the groups of study subjects [31].

Density gradient ultracentrifugation, nondenaturing gradient gel electrophoresis, and nuclear magnetic
resonance spectroscopy are the methods that are usually employed to measure HDL particle size, but they are difficult to apply in clinical settings due to their cost and complexity [8]. As one apoA-1 molecule is bound to each single HDL particle, however, the HDL-C/apoA-1 ratio has been reported to serve as a simple indicator of HDL particle size [32]. Both small HDL particles prior to cholesterol efflux and post-cholesterol efflux large HDL particles occur within arteriosclerotic plaque where the RCT system is activated. In recent years, there have been reports purporting to underline the importance of small HDL particles with strong cholesterol efflux capacity as an indicator of activation of the RCT system [7]. Due to the effect that lipid-poor HDL particles have in facilitating a reverse cholesterol transport system, we believe that cholesterol poor, apo A-1-rich HDL particles (i.e., producing a lower HDL-C/apoA-1 ratio) are likely to reduce the risk of ASCVD. Similar studies, which have shown that the quality of HDL matters more than quantity, support this hypothesis [4].

The patients enrolled in the present study were those with a high risk of ASCVD possessing risk factors for arteriosclerosis. Sung and co-workers who conducted studies using the HDL-C/apoA-1 ratio as an indicator of HDL particle size, as in our study, reported that the lower the HDL-C/apoA-1 ratio, the lower was the mortality of CVD and coronary artery calcium [20, 21]. Meanwhile, a study investigating development of CKD among healthy subjects yielded negative results indicating that the lower the HDL-C/apoA-1 ratio, the higher was the morbidity of CKD [33]. As described earlier, the disparity of results depending on subjects enrolled in studies may be relevant to the degree of progression of arteriosclerosis due to lipid metabolism abnormality.

Not only the metabolism of LDL, which is predominantly involved in the progression and suppression of atherosclerosis, but also that of HDL, is greatly affected by the serum TG level [34]. As can be seen from Fig. 4a, HDL particles are prone to downsizing when a subject is in a hypertriglyceridemic state. Fournier et al. also reported a negative
correlation between the HDL-C/apoA-1 ratio and the serum TG level, which lends support to our results [35]. It has been described that HDL particles are downsized in such a state, and that downsized HDL particles show depressed function, i.e., they are dysfunctional HDL particles [34]. However, it has also been reported that TG-rich, apoA-1-poor small dense HDL has an anti-atherogenic effect in patients with metabolic syndrome [36]. These points represent issues that still need to be clarified. We, therefore, examined the changes in the HDL particle size caused by variations of the serum TG level using a longitudinal research technique (Fig. 4b). The study demonstrated that the lower the serum TG level and the greater the likelihood of improvement of the hypertriglyceridemia, the greater the tendency for the HDL particles to grow into cholesterol-rich particles of larger size. This phenomenon may reflect conversion of small HDL particles into larger-sized HDL particles upon activation of RCT [7].

The present study also showed that under a hypertriglyceridemic state, the LDL particle size diminishes to yield increasingly downsized LDL particles [34] (Fig. 4c). This phenomenon, as for the case of changes of the HDL particle size, also may indicate, as shown in Fig. 4d, that improvement of hypertriglyceridemia results in amelioration of LDL metabolism, with a consequent trend toward increase of the LDL particle size, leading to suppression of the effect of LDL in promoting atherosclerosis progression.

Although it was a longitudinal study with temporal elements taken into account rather than an intervention study involving the use of lipid metabolism-improving drugs or lifestyle improvement, the present study was no more than an observational study; therefore, no reasonable conclusions can be drawn as to causal relationship of the findings gained. Nevertheless, the findings may show the interrelation between HDL and LDL metabolism.

In conjunction with the above phenomenon, the present study shows the possibility that downsizing of LDL particles potently giving rise to progression of arteriosclerosis as well as elevation of serum DHA concentration is a determining factor for downsizing of HDL particles. It would seem probable that the RCT system may be activated contrarily as a result of increased small HDL particles under the circumstances where progressive downsizing of LDL particles is associated with the consequent facilitation of arteriosclerosis progression due to the presence of risk factors for atherosclerosis. Likewise, increased levels of lecithin-cholesterol acyltransferase activity have been reported as an RCT-activating factor under the circumstances of progressing arteriosclerosis in the presence of lipid metabolism abnormality [37, 38]. Based on the above presumptions, we prepared Fig. 5 by adopting the changes in the LDL particle size and changes in the HDL particle size as indicators of RCT activation.

It has been reported that n-3 PUFAs derived from fish intake are endowed with a variety of protective effects on the cardiovascular system [3]. Our present research focuses on HDL metabolism which is deeply involved in suppression of atherosclerotic progression. A recent study in vitro has demonstrated an HDL-cholesterol efflux capacity-activating effect of EPA [39]. Although it might appear inappropriate for us to refer unitarily to disparities in respective study results regarding n-3 PUFAs and the RCT system because of the differences in research procedures, it would seem to be reasonable to infer that n-3 PUFAs play some role in improving HDL function. We are hopeful that our present results will lay some foundation

Fig. 5 Association between HDL-C/apoA-1 ratio AND LDL-Rm value. A positive correlation was observed between the LDL-Rm value and HDL-C/apoA-1, and the ∆ LDL-Rm value was also found to be weakly correlated with the ∆ HDL-C/apoA-1 ratio. HDL-C high-density lipoprotein cholesterol, apoA-1 apolipoprotein A-1, LDL-Rm relative LDL migration, ∆ absolute change from baseline to 6-month follow-up.
for elucidation of the mechanism whereby fish intake provides a cardiovascular event-suppressing effect.

**Study limitations and clinical implications**

Firstly, as several methods are available for evaluation of HDL particle size, investigations with other evaluation methods have to be pursued [8]. Secondly, another concern lies in the lack of biological testing of the hypothesis on which this study is based, i.e., small HDL particles = high cholesterol countertransport activity and large HDL particles = low cholesterol countertransport activity. Thirdly, no investigation has been done as to HDL particle downsizing and HDL function under a hypertriglycerideremic state. Intervention studies with DHA formulations are needed to elucidate the underlying mechanisms. Fourthly, investigation of the phospholipids, which account for the largest part of the constituents of HDL particles and which are partially involved in the function of HDL, is to be pursued for precise evaluation of the effects of HDL particle size [7, 40]. HDL particles were only evaluated in terms of the serum HDL-C level and apoA-1 level in this study, which did not include investigation of the HDL particle constituents. Various approaches have been attempted to determine the functions of HDL [8], and it is considered that evaluation of the function of HDL using a combination of approaches is necessary to examine the suppressive effect of HDL on ASCVD. Finally, this study does not demonstrate the relationship between the HDL-C/apoA-1 ratio, serum DHA level, and clinical indices or/and outcomes. In the future, an interventional study to investigate the causal relationship is needed.

**Conclusion**

Although there are numerous unresolved issues with regard to the differences in the ASCV-protective effects between EPA and DHA, an increased serum DHA level may be associated with decreased HDL-C/apoA-1 ratio, an indicator of estimated HDL particle size. Further studies are needed to investigate the useful clinical indices and outcomes of these patients.

**Acknowledgements** This work was supported by KAKENHI Grant number 16K09045 of the Japan Society for the Promotion of Science (JSPS). The authors would like to thank International Medical Information Center (http://www.imic.or.jp/services/translation.html) for the English language review. The authors would also like to thank Mr. Gary Cooper for his help in editing the English manuscript.
13. Castelli WP (1988) Cholesterol and lipids in the risk of coronary artery disease—the Framingham Heart Study. Can J Cardiol 4(Suppl A):5A–10A

14. Rader DJ, Tall AR (2012) The not-so-simple HDL story: Is it time to revise the HDL cholesterol hypothesis? Nat Med 18:1344–1346

15. AIM-HIGH Investigators, Boden WE, Probstfield JL, Anderson T, Chaitman BR, Desvignes-Nickens P, Koprowicz K, McBride R, Teo K, Weintraub W (2011) Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy. N Engl J Med 365:2255–2267

16. Barter PJ, Caulfield M, Eriksson M, Grundy SM, Kastelein JJ, Khaw KT, Leiter LA, Waters DD, Shear CL, Revkin JH, Buhr KA, Fisher MR, Tall AR, Brewer B, Investigators ILLUMINATE (2007) Effects of torcetrapib in patients at high risk for coronary events. N Engl J Med 357:2109–2122

17. Voight BF, Peloso GM, Orho-Melander M, Frikke-Schmidt R, Barbicic M, Jensen MK, Hing G, Hólín H, Ding ELJ, Johnson T, Schunkert H, Samani NJ, Clarke R, Hopewell JC, Thompson JF, Li M, Thorleifsson G, Newton-Cheh C, Musunuru K, Pirkrcusso JP, Saledeen D, Chen L, Stewart A, Schill A, Thorsteinsdottir U, Thorgeirsson D, Anand S, Engert JC, Morgan T, Sertorus J, Stoll M, Berger K, Martinelli N, Girelli D, McKeown PP, Patterson CC, Epstein SE, Devaney J, Burnett MS, Mooser V, Ripatti S, Surakka I, Nieminen MS, Sinisalo J, Kokkonen P, Neuvonen P, Hardy R, Tait D, Wild P, de Bakker PI, Klungel OH, Maitland-van de Zee AE, Peters BJ, de Boer A, Grobbbee DE, Kamphuisen PW, Deneer VH, Elbers CC, Onland-Moret NC, Hofker MH, Wijmenga C, Verschuren WM, Ubbels CC, van der Schouw YT, Rasheed A, Fassard P, Deissie S, Willer C, Do R, Ordoval AM, Beacar G, Moncke M, Mohlke KL, Daly MJ, Guiducci C, Burtt NP, Surit A, Gonzalez E, Purcell S, Marrugat J, Peden J, Erdmann J, Diemert P, Willenborg C, König IR, Fischer M, Hengstenberg C, Ziegler A, Buyssecaert I, Lambrecht D, Van de Werf F, Fox KA, El Mohktari NE, Rubin D, Schrezenmeir J, Schreiber S, Schäfer A, Danesh J, Blankenberg S, Roberts R, McPherson R, Watkins H, Hall AS, Overvad K, Rimm E, Boerwinkle E, Tybjaerg-Hansen A, Cuppen LA, Reilly MP, Melander O, Mannucci PM, Ardlissino D, Siscovick D, Eloua E, Stefansson K, O’Donnell CJ, Schramm V, Rader DJ, Peltonen L, Schwartz SM, Afshuler D, Katzenians S (2012) Plasma HDL cholesterol and risk of myocardial infarction: a mendelian randomisation study. Lancet 380:572–580

18. Khraa AV, Cuchel M, de la Llera-Moya M, Rodrigues A, Burke MF, Jafari K, French BC, Phillips JA, Muckavage ML, Wilensky RL, Mohler ER, Rothblatt GH, Rader DJ (2011) Cholesterol efflux capacity, high-density lipoprotein function, and atherosclerosis. N Engl J Med 364:127–135

19. Rohatgi A, Khraa A, Berry JD, Givens EG, Ayers CR, Wedin KE, Neeland IY, Yuhanna IS, Rader DR, de Lemos JA, Shaul PW (2014) HDL cholesterol efflux capacity and incident cardiovascular events. N Engl J Med 371:2383–2393

20. Sung KC, Wild SH, Byrne CD (2013) Controlling for apolipoprotein A-I concentrations changes the inverse direction of the relationship between high HDL-C concentration and a measure of pre-clinical atherosclerosis. Atherosclerosis 231:181–186

21. Sung KC, Ryu S, Wild SH, Byrne CD (2015) An increased high-density lipoprotein cholesterol/apolipoprotein A-I ratio is associated with increased cardiovascular and all-cause mortality. Heart 101:553–558

22. Kim DS, Burt AA, Rosenthal EA, Ranchalis JE, Eintracht JF, Hatsuaki TS, Furlong CE, Marcovina S, Albers JJ, Jarvik GP (2014) HDL-3 is a superior predictor of carotid artery disease in a case–control cohort of 1725 participants. J Am Heart Assoc 3:e00902

23. Imai E, Horio M, Nitta K, Yamagata K, Iseki K, Hara S, Ura N, Kiyohara Y, Hirakata H, Watanabe T, Moriayama T, Ando Y, Inaguma D, Nair A, Iso H, Waki K, Yasuda Y, Usukamo Y, Ito S, Makino H, Hishida A, Matsuo S (2007) Estimation of glomerular filtration rate by the MDRD study equation modified for Japanese patients with chronic kidney disease. Clin Exp Nephrol 11:41–50

24. Sniderman AD, Blank D, Zakario R, Bergeron J, Frohlich J (2003) Triglycerides and small dense LDL: the twin Achilles heels of the Friedewald formula. Clin Biochem 36:499–504

25. Hirano T, Ito Y, Yoshino G (2005) Measurement of small dense low-density lipoprotein particles. J Atheroscler Thromb 12:67–72

26. Tani S, Matsumoto M, Nagao K, Hirose I, Nakane A, Kato N, Honda S, Tobe K, Takahashi E, Waki K, Yabu K, Takeda S, Kihara S (2014) Association of triglyceride-rich lipoprotein markers and low-density lipoprotein heterogeneity with cardiovascular risk: effectiveness of polyacrylamide-gel electrophoresis as a method of determining low-density lipoprotein particle size. J Cardiol 63:60–68

27. García-Sánchez C, Posadas-Romero C, Posadas-Sánchez R, Carreño-Torres E, Rodríguez-Pérez JM, Jáuregui-Rojas JG, Martínez-Sánchez C, Fragojo JM, González-Pacheco H, Vargas-Alarcón G, Pérez-Méndez O (2015) Low concentrations of phospholipids and plasma HDL cholesterol subclasses in asymptomatic subjects with high coronary calcium scores. Atherosclerosis 238:250–255

28. Arsenault BJ, Lemieux I, Després JP, Gagnon P, Wareham NJ, Stroes ES, Kastelein JJ, Khaw KT, Boekholdt SM (2009) HDL cholesterol particle size and the risk of coronary heart disease in apparently healthy women and men: the EPIC-Norfolk prospective population study. Atherosclerosis 206:276–281

29. Arsenault BJ, Lemieux I, Després JP, Wareham NJ, Stroes ES, Kastelein JJ, Khaw KT, Boekholdt SM (2010) Comparison between gradient gel electrophoresis and nuclear magnetic resonance spectroscopy in estimating coronary heart disease risk associated with LDL and HDL particle size. Clin Chem 56:789–798

30. Yu S, Yarnell JW, Sweetnam P, Bolton CH (2003) High density lipoprotein subfractions and the risk of coronary heart disease: 9-years follow-up in the Caerphilly Study. Atherosclerosis 166:331–338

31. Superko HR, Superko SM, Nasir K, Agatston A, Barrett BC (2013) Omega-3 fatty acid blood levels: clinical significance and controversy. Circulation 128:2154–2161

32. Mason NA, Giuliani F, Paynter NP, Jordan P, Mora S (2013) A comparison of the theoretical relationship between HDL size and the ratio of HDL cholesterol to apolipoprotein A-I with experimental results from the Women’s Health Study. Clin Chem 59:949–958

33. Bae JC, Han JM, Kwon S, Jee JH, Yu TY, Lee MK, Kim JH (2016) LDL-C/apoB and HDL-C/apoA-1 ratios predict incident chronic kidney disease in a large apparently healthy cohort. Atherosclerosis 251:170–176

34. Miller M, Stone NJ, Ballantyne C, Brewer Jr, Criqui MH, Ginsberg HN, Goldberg AC, Howard WJ, Jacobson MS, Krat-Etherton PM, Lennie TA, Levi M, Mazzone T, Pennathur S (2011); American Heart Association Clinical Lipidology, Thrombosis, and Prevention Committee of the Council on Nutrition, Physical Activity, and Metabolism; Council on Arteriosclerosis, Thrombosis and Vascular Biology; Council on Cardiovascular Nursing; Council on the Kidney in Cardiovascular Disease. Triglycerides and cardiovascular disease: a scientific statement from the American Heart Association. Circulation 123:2292–2333

35. Fournier N, Ager V, Cogny A, Vedie B, Giral P, Simon A, Moatti N, Paul JL (2001) Analysis of the relationship between triglyceride demia and HDL–phospholipid concentrations: consequences on the efflux capacity of serum in the F5AH system. Atherosclerosis 157:315–323

36. de Souza JA, Vindis C, Hansel B, Négre-Salvayre A, Thérond P, Serrano CV Jr, Chantepie S, Salvayre R, Bruckert E, Chapman MJ, Kontush A (2008) Metabolic syndrome features small,
apolipoprotein A-I-poor, triglyceride-rich HDL3 particles with defective anti-apoptotic activity. Atherosclerosis 197:84–94
37. Chung BH, Segrest JP, Franklin F (1998) In vitro production of beta-very low density lipoproteins and small, dense low density lipoproteins in mildly hypertriglyceridemic plasma: role of activities of lecithin:cholesterol acyltransferase, cholesterylester transfer proteins and lipoprotein lipase. Atherosclerosis 141:209–225
38. Tani S, Takahashi A, Nagao K, Hirayama A (2016) Association of lecithin-cholesterol acyltransferase activity measured as a serum cholesterol esterification rate and low-density lipoprotein heterogeneity with cardiovascular risk: a cross-sectional study. Heart Vessels 31:831–840
39. Tanaka N, Ishida T, Nagao M, Mori T, Monguchi T, Sasaki M, Mori K, Kondo K, Nakajima H, Honjo T, Irino Y, Toh R, Shinohara M, Hirata K (2014) Administration of high dose eicosapentaenoic acid enhances anti-inflammatory properties of high-density lipoprotein in Japanese patients with dyslipidemia. Atherosclerosis 237:577–583
40. Kontush A, Chapman MJ (2006) Functionally defective high-density lipoprotein: a new therapeutic target at the crossroads of dyslipidemia, inflammation, and atherosclerosis. Pharmacol Rev 58:342–374